Assessing the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes
Official title: Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)
Run by Aristotle University Of Thessaloniki · NCT06890013 · Data updated 2026-11-12
This study is testing if measuring blood vessel response can help predict outcomes for patients with serious heart conditions like heart attacks.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Aristotle University Of Thessaloniki Academic / other |
| Locations | 1 site (Thessaloniki) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | June 1, 2026 |
| Study ends | November 1, 2026 |
| Registry record updated | March 2, 2026 |
| Trial ID | NCT06890013 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old who are hospitalized due to acute coronary syndromes.
✕Probably not a fit
Patients with rare types of acute coronary syndromes or significant comorbidities that limit their survival may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the predictive role of flow mediated dilatation (FMD) in patients with acute coronary syndromes, including STEMI and NSTEMI. It will combine FMD assessments with echocardiographic and biochemical indices to enhance understanding of endothelial function in these patients. The study will utilize the novel Cor-IS technology to gather data and insights. Participants will be monitored to assess the relationship between FMD and clinical outcomes.
Why it matters
Potential benefit: If successful, this study could improve the predictive capabilities for acute coronary syndromes, leading to better patient management and outcomes.
How similar studies have gone: While the specific approach of this study may be novel, similar studies assessing endothelial function in acute coronary syndromes have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 years 2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI) 3. Capability of providing written informed consent 4. Patients able to comply with the follow-up schedule of the study Exclusion Criteria: 1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction 2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome 3. Patients with congenital heart disease 4. Age \> 85 years 5. Patients with end stage chronic kidney disease 6. Patients with active malignancy or autoimmune diseases which limit their survival 7. Patients with expected survival \< 1 year due to other reasons 8. Suboptimal echocardiographic windows 9. Inability to provide written consent 10. Inability to comply with the follow-up schedule of the study 11. Pregnancy 12. Use of intravenous drugs
Where it's running
-
Ippokratio General Hospital
Thessaloniki, Greece Recruiting
Study contacts
- Principal investigator: Christodoulos E. Papadopoulos, PhD — Aristotle University of Thessaloniki, Greece
- Study coordinator: Christodoulos E. Papadopoulos, PhD
- Email: chrpapado@gmail.com
- Phone: 2313312343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Local and systemic macrophage activation in coronary and peripheral artery disease
This study tests whether macrophage activity inside coronary and peripheral arteries relates to circulating monocyte subtypes in people with stable and acute artery disease.
-
Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty
This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.